Altimmune (NASDAQ:ALT) Stock Rating Upgraded by Wall Street Zen

Altimmune (NASDAQ:ALT) was upgraded by stock analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued to investors on Saturday.

Several other research analysts have also issued reports on ALT. HC Wainwright restated a “buy” rating and issued a $20.00 price target (down from $25.00) on shares of Altimmune in a research report on Monday, May 18th. Truist Financial started coverage on Altimmune in a research note on Wednesday, March 18th. They issued a “buy” rating and a $12.00 target price on the stock. Citigroup restated a “market outperform” rating on shares of Altimmune in a report on Tuesday, June 2nd. Citizens Jmp lowered their price target on Altimmune from $14.00 to $11.00 and set a “market outperform” rating for the company in a research note on Thursday, May 14th. Finally, William Blair reaffirmed a “market perform” rating on shares of Altimmune in a research note on Thursday, March 5th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $15.71.

Altimmune Stock Performance

ALT stock opened at $2.82 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 29.56 and a quick ratio of 29.56. The company has a 50 day moving average price of $2.92 and a 200 day moving average price of $3.75. Altimmune has a fifty-two week low of $2.56 and a fifty-two week high of $6.44. The stock has a market capitalization of $548.41 million, a PE ratio of -3.03 and a beta of 0.21.

Altimmune (NASDAQ:ALT) last released its earnings results on Wednesday, May 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 42.57%. Analysts forecast that Altimmune will post -0.69 EPS for the current year.

Hedge Funds Weigh In On Altimmune

A number of large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Altimmune by 23.3% in the 3rd quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock valued at $24,029,000 after purchasing an additional 1,206,514 shares during the period. State Street Corp grew its holdings in shares of Altimmune by 42.2% during the fourth quarter. State Street Corp now owns 5,119,703 shares of the company’s stock worth $18,482,000 after buying an additional 1,518,448 shares in the last quarter. Geode Capital Management LLC raised its position in Altimmune by 13.6% in the 4th quarter. Geode Capital Management LLC now owns 2,292,410 shares of the company’s stock valued at $8,278,000 after buying an additional 275,025 shares during the last quarter. Two Sigma Investments LP lifted its stake in Altimmune by 356.6% in the 3rd quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock valued at $7,528,000 after acquiring an additional 1,559,562 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in Altimmune by 140.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,349,293 shares of the company’s stock worth $4,871,000 after acquiring an additional 787,036 shares during the last quarter. Institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.